ERBB2 and breast cancer: Molecular markers such as ER, PR, and Her2/neu, which also serve as prognostic factors, are distributed differently in premenopausal and postmenopausal BC patients, with a tendency for overexpression of the triple-negative cases in premenopausal ones [39].